BiomeDx presents multi-centric validation of BiomeOne® at the ESMO Congress 2022
VIENNA, September 19th:
The ESMO congress 2022 was held in Paris, between the 9-14 September 2022 (https://www.esmo.org/meetings/past-meetings/esmo-congress-2022). BiomeDx presented their latest results from the validation study of BiomeOne®, a stool-based microbiome test to predict the response to cancer immunotherapy (immune checkpoint inhibitors). This is the first stool-based test of its kind to be launched into the market, and will certainly pave the way to the development of non-invasive tests based on the intestinal microbiome.
About BiomeOne®
BiomeOne has been CE-IVD marked in May 2022, and is now available for purchase in our website. The test has been released for ICI response prediction in non-small-cell lung cancer, renal cell carcinoma and malignant melanoma patients. Ongoing research aims to further expand the applicability to other tumour types. Read more on BiomeOne.
About BiomeDx®
Biome Diagnostics GmbH (BiomeDx) is world leader in microbiome diagnostic products for oncology. The Austrian based MedTech company is committed to advance precision medicine by pioneering microbiome-based technologies that transform cancer care. The company is strategically positioned at the intersection of state-of-the-art DNA sequencing and advanced machine learning algorithms to develop first in class technologies for routine clinical practice. It is the world first microbiome company certified according to ISO 13485:2016 and ISO 9001:2015.
Presented poster: BiomeOne: Multi-centric validation of a novel microbiome-based biomarker to predict response to cancer immunotherapy